Paper Details

  1. Home
  2. Paper Details

Neratinib kills B-RAF V600E melanoma via ROS-dependent autophagosome formation and death receptor signaling.

Author: BoothLaurence, DentPaul, KirkwoodJohn M, PoklepovicAndrew

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

This study investigated the impact of neratinib, an ERBB family and MAP4K inhibitor, on melanoma cells expressing B-RAF V600E. Neratinib was found to synergize with HDAC inhibitors to kill melanoma cells and was shown to activate certain pathways while inactivating others, leading to increased autophagy and cell death.
Paper Details　
Original Abstract of the Article :
Melanoma cells expressing mutant B-RAF V600E are susceptible to treatment with the combination of a B-RAF inhibitor and a MEK1/2 inhibitor. We investigated the impact of the ERBB family and MAP4K inhibitor neratinib on the biology of PDX isolates of cutaneous melanoma expressing B-RAF V600E. Neratin...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1111/pcmr.13014

データ提供：米国国立医学図書館（NLM）

Neratinib: A Novel Approach to Targeting Melanoma

Melanoma, a type of skin cancer, can be aggressive and difficult to treat. This study explores the potential of neratinib, an inhibitor of the ERBB family and MAP4K, as a targeted therapy for melanoma cells expressing the mutant B-RAF V600E. It's like discovering a hidden pathway through the vast and challenging desert landscape of melanoma treatment.

Neratinib: A Synergistic Approach to Fighting Melanoma

The study found that neratinib synergized with HDAC inhibitors to kill melanoma cells. This finding suggests that neratinib, in combination with other therapies, may be a promising approach to treating melanoma. It's like finding a combination of desert plants that work together to create a more robust and effective remedy.

Unlocking the Potential of Neratinib for Melanoma Treatment

This research provides valuable insights into the potential of neratinib as a targeted therapy for melanoma. It offers hope for new and effective treatment options for patients with this challenging disease. Just as a desert explorer discovers a new and promising route, this study paves the way for future research and clinical trials to unlock the full potential of neratinib in melanoma treatment.

Dr.Camel's Conclusion

This study offers a glimmer of hope for patients battling melanoma. It highlights the importance of exploring new and innovative therapies, such as neratinib, to improve treatment outcomes and offer a brighter future for those affected by this challenging disease.

Date :
  1. Date Completed 2022-03-17
  2. Date Revised 2022-03-17
Further Info :

Pubmed ID

34482636

DOI: Digital Object Identifier

10.1111/pcmr.13014

Related Literature

Article Analysis
・Effects of neratinib・Effects of neratinib
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.